

Michael D Wyatt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8050424/publications.pdf>

Version: 2024-02-01

76
papers

6,788
citations

136950

32
h-index

76900

74
g-index

78
all docs

78
docs citations

78
times ranked

10534
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. <i>European Journal of Medicinal Chemistry</i> , 2022, 227, 113926.	5.5	6
2	Cis- and trans-resveratrol have opposite effects on histone serine-ADP-ribosylation and tyrosine induced neurodegeneration. <i>Nature Communications</i> , 2022, 13, .	12.8	12
3	Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9916-9925.	6.4	9
4	Clinical significance of a pvr1 4 encoded gene Nectin-4 in metastasis and angiogenesis for tumor relapse. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 245-259.	2.5	38
5	Microbes as Drugs: The Potential of Pharmabiotics. <i>Pharmacotherapy</i> , 2020, 40, 102-106.	2.6	8
6	Inhibition of the Dead Box RNA Helicase 3 Prevents HIV-1 Tat and Cocaine-Induced Neurotoxicity by Targeting Microglia Activation. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 209-223.	4.1	11
7	Pharmacological inhibition of DEAD-Box RNA Helicase 3 attenuates stress granule assembly. <i>Biochemical Pharmacology</i> , 2020, 182, 114280.	4.4	19
8	Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. <i>Lancet Oncology</i> , The, 2020, 21, e575-e588.	10.7	15
9	Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor. <i>ChemMedChem</i> , 2020, 15, 1058-1066.	3.2	10
10	Panaxynol, a bioactive component of American ginseng, targets macrophages and suppresses colitis in mice. <i>Oncotarget</i> , 2020, 11, 2026-2036.	1.8	11
11	Microglia morphology and proinflammatory signaling in the nucleus accumbens during nicotine withdrawal. <i>Science Advances</i> , 2019, 5, eaax7031.	10.3	61
12	Thiopurine-induced mitotic catastrophe in <i>Rad51</i> -deficient mammalian cells. <i>Environmental and Molecular Mutagenesis</i> , 2018, 59, 38-48.	2.2	1
13	Potential unintended consequences of getting rigorous with scientific rigor. <i>Carcinogenesis</i> , 2018, 39, 26-27.	2.8	1
14	The soluble nectin-4 ecto-domain promotes breast cancer induced angiogenesis via endothelial Integrin- β 4. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 102, 151-160.	2.8	37
15	Nectin-4 is a breast cancer stem cell marker that induces WNT/ β -catenin signaling via Pi3k/Akt axis. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 89, 85-94.	2.8	68
16	Identification of novel cancer therapeutic targets using a designed and pooled shRNA library screen. <i>Scientific Reports</i> , 2017, 7, 43023.	3.3	33
17	Human Papillomavirus Type 16 L2 DNA Methylation in Exfoliated Cervical Cells From College-Age Women. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 332-337.	1.9	2
18	Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade. <i>Biochemical Pharmacology</i> , 2016, 105, 23-33.	4.4	21

#	ARTICLE	IF	CITATIONS
19	Iterative Conversion of Cyclin Binding Groove Peptides into Druglike CDK Inhibitors with Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 433-442.	6.4	12
20	Regulatory and clinical considerations for biosimilar oncology drugs. <i>Lancet Oncology</i> , The, 2014, 15, e594-e605.	10.7	99
21	5-Fluorouracil mediated anti-cancer activity in colon cancer cells is through the induction of Adenomatous Polyposis Coli: Implication of the long-patch base excision repair pathway. <i>DNA Repair</i> , 2014, 24, 15-25.	2.8	39
22	Current assessment of polo-like kinases as anti-tumor drug targets. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 773-789.	5.0	39
23	The contribution of heavy metals in cigarette smoke condensate to malignant transformation of breast epithelial cells and in vivo initiation of neoplasia through induction of a PI3K/AKT/NF κ B cascade. <i>Toxicology and Applied Pharmacology</i> , 2014, 274, 168-179.	2.8	35
24	Advances in Understanding the Coupling of DNA Base Modifying Enzymes to Processes Involving Base Excision Repair. <i>Advances in Cancer Research</i> , 2013, 119, 63-106.	5.0	11
25	SMUG1 but not UNG DNA glycosylase contributes to the cellular response to recovery from 5-fluorouracil induced replication stress. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2013, 743-744, 26-32.	1.0	16
26	Silver-based nanoparticles induce apoptosis in human colon cancer cells mediated through p53. <i>Nanomedicine</i> , 2013, 8, 1307-1322.	3.3	119
27	Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC. <i>Carcinogenesis</i> , 2013, 34, 277-286.	2.8	74
28	Targeting Subcellular Localization through the Polo-Box Domain: Non-ATP Competitive Inhibitors Recapitulate a PLK1 Phenotype. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1683-1692.	4.1	22
29	Quinacrine-Mediated Autophagy and Apoptosis in Colon Cancer Cells Is Through a p53- and p21-Dependent Mechanism. <i>Oncology Research</i> , 2012, 20, 81-91.	1.5	89
30	Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics. <i>Biochemical Pharmacology</i> , 2012, 83, 741-746.	4.4	23
31	Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. <i>International Journal of Cancer</i> , 2012, 130, 1660-1670.	5.1	130
32	The Homologous Recombination Protein RAD51D Mediates the Processing of 6-Thioguanine Lesions Downstream of Mismatch Repair. <i>Molecular Cancer Research</i> , 2011, 9, 206-214.	3.4	11
33	PLK1 as an oncology target: current status and future potential. <i>Drug Discovery Today</i> , 2011, 16, 619-625.	6.4	89
34	Whole Organism Based Techniques and Approaches in Early Stage Oncology Drug Discovery-Patents and Trends. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2011, 5, 183-191.	0.6	1
35	Abstract 3240: Development of non-ATP competitive, PLK1 selective inhibitors. , 2011, , ,		0
36	RAD51D protects against MLH1-dependent cytotoxic responses to O6-methylguanine. <i>DNA Repair</i> , 2010, 9, 458-467.	2.8	19

#	ARTICLE	IF	CITATIONS
37	DNA damage in barn swallows (<i>Hirundo rustica</i>) from the Chernobyl region detected by use of the comet assay. <i>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</i> , 2010, 151, 271-277.	2.6	48
38	Cation Exchange on the Surface of Gold Nanorods with a Polymerizable Surfactant: Polymerization, Stability, and Toxicity Evaluation. <i>Langmuir</i> , 2010, 26, 9328-9333.	3.5	87
39	Differential effects of reactive nitrogen species on DNA base excision repair initiated by the alkyladenine DNA glycosylase. <i>Carcinogenesis</i> , 2009, 30, 2123-2129.	2.8	43
40	Participation of DNA repair in the response to 5-fluorouracil. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 788-799.	5.4	200
41	Cellular Uptake and Cytotoxicity of Gold Nanorods: Molecular Origin of Cytotoxicity and Surface Effects. <i>Small</i> , 2009, 5, 701-708.	10.0	927
42	Uracil in DNA: Consequences for carcinogenesis and chemotherapy. <i>Biochemical Pharmacology</i> , 2008, 76, 697-706.	4.4	65
43	DNA damage and homologous recombination signaling induced by thymidylate deprivation. <i>Biochemical Pharmacology</i> , 2008, 76, 987-996.	4.4	16
44	Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase. <i>DNA Repair</i> , 2008, 7, 162-169.	2.8	36
45	Induction of intrachromosomal homologous recombination in human cells by raltitrexed, an inhibitor of thymidylate synthase. <i>DNA Repair</i> , 2008, 7, 1624-1635.	2.8	16
46	One-pot synthesis of silica-coated magnetic plasmonic tracer nanoparticles. <i>Chemical Communications</i> , 2008, , 6140.	4.1	29
47	Methylating Agents and DNA Repair Responses: Methylated Bases and Sources of Strand Breaks. <i>Chemical Research in Toxicology</i> , 2006, 19, 1580-1594.	3.3	372
48	Developmental abnormalities in multiple proliferative tissues of <i>ApcMin/+</i> mice. <i>International Journal of Experimental Pathology</i> , 2006, 87, 227-236.	1.3	41
49	Determination of apoptosis, uracil incorporation, DNA strand breaks, and sister chromatid exchanges under conditions of thymidylate deprivation in a model of BER deficiency. <i>Biochemical Pharmacology</i> , 2005, 70, 1458-1468.	4.4	27
50	Gold Nanoparticles Are Taken Up by Human Cells but Do Not Cause Acute Cytotoxicity. <i>Small</i> , 2005, 1, 325-327.	10.0	2,190
51	Effects of Substrate Specificity on Initiating the Base Excision Repair of N-Methylpurines by Variant Human 3-Methyladenine DNA Glycosylases. <i>Chemical Research in Toxicology</i> , 2005, 18, 87-94.	3.3	16
52	Effect of Protein Binding on Ultrafast DNA Dynamics: Characterization of a DNA:APE1 Complex. <i>Biophysical Journal</i> , 2005, 89, 4129-4138.	0.5	32
53	Oxanine DNA Glycosylase Activity from Mammalian Alkyladenine Glycosylase. <i>Journal of Biological Chemistry</i> , 2004, 279, 38177-38183.	3.4	51
54	Involvement of base excision repair in response to therapy targeted at thymidylate synthase. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 747-53.	4.1	15

#	ARTICLE	IF	CITATIONS
55	Active-Site Clashes Prevent the Human 3-Methyladenine DNA Glycosylase from Improperly Removing Bases. <i>Chemistry and Biology</i> , 2002, 9, 1033-1041.	6.0	29
56	Influence of DNA structure on hypoxanthine and 1,N6-ethenoadenine removal by murine 3-methyladenine DNA glycosylase. <i>Carcinogenesis</i> , 2000, 21, 901-908.	2.8	29
57	Molecular basis for discriminating between normal and damaged bases by the human alkyladenine glycosylase, AAG. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 13573-13578.	7.1	219
58	3-methyladenine DNA glycosylases: structure, function, and biological importance. <i>BioEssays</i> , 1999, 21, 668-676.	2.5	173
59	3-methyladenine DNA glycosylases: structure, function, and biological importance. <i>BioEssays</i> , 1999, 21, 668-676.	2.5	3
60	Mammalian 3-methyladenine DNA glycosylase protects against the toxicity and clastogenicity of certain chemotherapeutic DNA cross-linking agents. <i>Cancer Research</i> , 1998, 58, 3965-73.	0.9	39
61	Determination of the DNA Sequence Specificity of Alkylation Damage Using Cleavage-Based Assays. , 1997, 90, 147-156.		5
62	The sequence specificity of alkylation for a series of benzoic acid mustard and imidazole-containing distamycin analogues: the importance of local sequence conformation. <i>Nucleic Acids Research</i> , 1997, 25, 2359-2364.	14.5	6
63	Base excision repair deficient mice lacking the Aag alkyladenine DNA glycosylase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 13087-13092.	7.1	215
64	Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9. <i>British Journal of Cancer</i> , 1997, 76, 1596-1603.	6.4	31
65	Alkylation specificity for a series of distamycin analogues that tether chlorambucil. <i>Anti-cancer Drug Design</i> , 1997, 12, 49-60.	0.3	3
66	Novel cytotoxic DNA sequence and minor groove targeted photosensitizers: Conjugates of pyrene and netropsin analogues. <i>Bioorganic and Medicinal Chemistry</i> , 1995, 3, 623-629.	3.0	7
67	DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. <i>Nucleic Acids Research</i> , 1995, 23, 81-87.	14.5	92
68	Sequence specificity of alkylation for a series of nitrogen mustard-containing analogs of distamycin of increasing binding site size: evidence for increased cytotoxicity with enhanced sequence specificity. <i>Biochemistry</i> , 1995, 34, 13034-13041.	2.5	41
69	Design, synthesis and biological evaluation of benzoic acid mustard derivatives of imidazole-containing and C-terminal carboxamide analogues of distamycin. <i>Drug Design and Discovery</i> , 1995, 12, 323-35.	0.3	2
70	Probing the importance of the second chloroethyl arm of a benzoic acid mustard derivative of an imidazole-containing analogue of distamycin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1994, 4, 2421-2424.	2.2	11
71	Synthesis and DNA binding properties of a series of N to C linked and imidazole containing analogues of distamycin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1994, 4, 801-806.	2.2	11
72	GC Sequence Specific Recognition by an N-Formamido, C-Terminus-Modified and Imidazole-Containing Analog of Netropsin. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 4073-4075.	6.4	9

#	ARTICLE	IF	CITATIONS
73	Structure-activity relationship of a series of nitrogen mustard- and pyrrole-containing minor groove-binding agents related to distamycin. <i>Anti-cancer Drug Design</i> , 1994, 9, 511-25.	0.3	5
74	In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 863-870.	6.4	51
75	GC base sequence recognition by oligoimidazolecarboxamide and C-terminus-modified analogs of distamycin deduced from circular dichroism, proton nuclear magnetic resonance, and methidiumpropylethylenediaminetetraacetate-iron(II) footprinting studies. <i>Biochemistry</i> , 1993, 32, 4237-4245.	2.5	392
76	Design, synthesis, and biological evaluation of DNA sequence and minor groove selective alkylating agents. <i>Anti-cancer Drug Design</i> , 1993, 8, 173-92.	0.3	11